Product Description
Liraglutide is a derivative of GLP?1 and shares 97% amino acid sequence homology with its parent molecule 9. GLP?1 is a polypeptide incretin hormone secreted by the L?cells of the gastrointestinal tract in response to nutrients in the lumen. It causes a glucose dependent stimulation of insulin secretion 10, reduction in plasma glucagon concentrations 11, delayed gastric emptying 12, appetite suppression 13, 14, and an increase in heart rate (Fig. 1) 15.
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: Europe
Company Founding Year: 1923
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, Denmark, France, Germany, Hong Kong, India, Israel, Malaysia, Mexico, Poland, Portugal, Russia, Spain, Switzerland, United States
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Phase 2: Osteoarthritis, Knee|Synovitis
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07225829 |
INFLAM MOTION | P2 |
Recruiting |
Synovitis|Osteoarthritis, Knee |
2026-05-01 |
2025-11-11 |
Primary Endpoints|Treatments |
|
NCT05268237 |
BIOL-001 | P2 |
Recruiting |
Type 2 Diabetes |
2025-12-01 |
50% |
2025-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT07225816 |
Injected | P1 |
Recruiting |
Obesity |
2026-06-19 |
88% |
2025-11-26 |
|
NCT06449703 |
THDB0213L01 | P1 |
Recruiting |
Healthy Volunteers |
2024-06-16 |
12% |
2024-06-28 |
|
CTR20232848 |
CTR20232848 | P1 |
Completed |
Type 2 Diabetes |
2023-10-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2018-002425-34 |
2018-002425-34 | P2 |
Completed |
Type 2 Diabetes |
2024-12-13 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-508504-38-00 |
NN8022-4392 | P3 |
Active, not recruiting |
Obesity |
2027-01-15 |
2025-05-02 |
Treatments |
|
NCT06559722 |
THDB0213L03 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2025-10-01 |
14% |
2024-08-20 |
|
2020-000546-34 |
2020-000546-34 | P3 |
Active, not recruiting |
Obesity |
2023-12-03 |
18% |
2022-03-13 |
Treatments |
CTR20210173 |
CTR20210173 | P3 |
Completed |
Type 2 Diabetes |
2023-11-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03115424 |
NCT03115424 | P3 |
Completed |
Obesity |
2023-10-04 |
30% |
2024-09-28 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT04775082 |
SCALE KIDS | P3 |
Active, not recruiting |
Obesity |
2023-08-01 |
18% |
2023-09-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20200348 |
CTR20200348 | P3 |
Completed |
Type 2 Diabetes |
2023-02-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20250744 |
CTR20250744 | P3 |
Active, not recruiting |
Type 2 Diabetes |
None |
2026-01-25 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20201449 |
CTR20201449 | P3 |
Active, not recruiting |
Obesity|Overweight |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20211086 |
CTR20211086 | P3 |
Recruiting |
Type 2 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT06439056 |
NEX-22-01 | P1 |
Completed |
Type 2 Diabetes |
2025-07-18 |
88% |
2025-09-24 |
Primary Endpoints |
CTR20241536 |
CTR20241536 | P1 |
Completed |
Type 2 Diabetes |
2024-06-25 |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/05/2026 |
News Article |
Lexaria Announces Positive Final Results From Human Pilot Study #5 |
|
01/30/2026 |
News Article |
Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030 |
|
01/28/2026 |
News Article |
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America |
|
01/08/2026 |
News Article |
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study |